Latest Advanced Prostate Cancer News2017-10-19T10:43:14-04:00

Provenge Receives A Positive National Determination from CMS

Yesterday Dendreon, the producers of Provenge, received word from the FDA that their plant in California had been approved to manufacture Provenge. This afternoon they received a positive response from the Centers for Medicare and [...]

Malecare Responds to the New York Times About the High Costs of Advanced Prostate Cancer Treatments

Darryl, the Malecare Executive Director, posted an organizational response to yesterday's New York Times Article on the newly approved advanced prostate cancer drugs and their economic impact. I thought that I would share his insightful [...]

The High Cost of Prostate Cancer Treatments – How Telling Are the Comments

Today’s New York Times carried a front page article about the high cost of the new prostate cancer treatments. This article seems to be the talk of the town and the talk (based on the [...]

On The Horizon – Xgeva (denosumab) To Prevent or Slow Down Bone Mets

Yesterday, Amgen announced that it had submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) to expand its license for XGEVA® (denosumab) to treat men with castrate-resistant prostate cancer [...]

Go to Top